Candace Soddu Quinn, LMSW | |
129 Dillon Drive, Spartanburg, SC 29307 | |
(864) 582-7588 | |
(864) 562-4117 |
Full Name | Candace Soddu Quinn |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 129 Dillon Drive, Spartanburg, South Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003534025 | NPI | - | NPPES |
AD10SP | Medicaid | SC |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | (* (Not Available)) | Secondary |
1041C0700X | Social Worker - Clinical | 16607 (South Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Candace Soddu Quinn, LMSW 129 Dillon Drive, Spartanburg, SC 29307 Ph: (864) 641-8664 | Candace Soddu Quinn, LMSW 129 Dillon Drive, Spartanburg, SC 29307 Ph: (864) 582-7588 |
News Archive
Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Nanyang Technological University, Singapore scientists have developed a 'contact lens' patch with microneedles that could provide a painless and efficient alternative to current methods of treating eye diseases such as glaucoma and macular degeneration.
The researchers also report that a sedentary lifestyle, in addition to aging, puts older people at risk for heart failure, the leading cause of hospitalizations for patients over 65 and a condition that affects eight out of every 1,000 people older than 70.
The extraordinary action of a new cellular therapy came to light as a result of powerful PET and SPECT imaging in a recent study reported in the April issue of the Journal of Nuclear Medicine.
Using immunotherapy biologic agents that stimulate the body's immune system pediatric oncologists have achieved the first substantial increase in over a decade in cure rates for the childhood cancer neuroblastoma. A newly released study shows that the new treatment improved two-year survival rates by 20 percent, compared to standard treatment for an aggressive form of neuroblastoma, a cancer of the nervous system.
› Verified 8 days ago